Form 4: TG Therapeutics CFO Sean Power Reports Acquisition of 87,500 Shares of Common Stock

Sean Power, CFO of TG Therapeutics, reports acquiring 87,500 shares of common stock through a grant of restricted shares.

Summary

• On January 29, 2025, Sean A. Power, CFO of TG Therapeutics, acquired 87,500 shares of common stock.
• These shares were acquired through a grant of restricted shares.
• One-quarter of the restricted shares will vest equally on January 1, 2026, January 1, 2027, January 1, 2028, and January 1, 2029.
• Following the transaction, Power beneficially owns 708,111 shares of TG Therapeutics common stock, including restricted shares that vest over various time periods.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The acquisition of shares by the CFO could be interpreted slightly positively, but it's a routine event.

Positives

• The CFO's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider ownership is often viewed favorably.

Key Dates